Lupin Secures Tentative FDA Nod for Generic Pitolisant Tablets — Lupin Pharmaceuticals, Inc.

Event summary

Lupin received tentative FDA approval for its Pitolisant Tablets (4.45mg and 17.8mg) as bioequivalent to Wakix®.
The product will be manufactured at Lupin's Nagpur facility in India.
Pitolisant is indicated for the same uses as Wakix®, a treatment for narcolepsy.
This marks Lupin's entry into the central nervous system (CNS) generics market in the U.S.

The big picture

Lupin's tentative FDA approval for Pitolisant Tablets expands its footprint in the U.S. CNS generics market, a segment increasingly competitive as patent cliffs approach. The approval underscores Lupin's strategy of leveraging its Indian manufacturing capabilities to produce complex generics for global markets. Success here could further solidify its position as a top-tier generic drug manufacturer, but execution risks remain high.

What we're watching

Market Entry Timing: Whether Lupin can secure final FDA approval and launch before patent expirations or competitive pressures intensify.
Manufacturing Scalability: The pace at which Lupin can scale production at its Nagpur facility to meet U.S. demand.
Pricing Strategy: How Lupin will position its generic Pitolisant Tablets against Bioprojet's branded Wakix® in the U.S. market.